ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0136

Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study

RITESH KUMAR MISHRA1, SUBIN PHILIP2, RIZWANA NAUSHAD2, AISHWARYA GOPAL3, Chengappa Kavadichanda2, CHRISTINA MARIASELVAM2, RAJESH N G2, Molly mary Thabah3 and VIR SINGH NEGI2, 1JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, 2JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, 3JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India

Meeting: ACR Convergence 2025

Keywords: antiphospholipid syndrome, longitudinal studies, Lupus nephritis, Nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0115–0144) Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Renal involvement in primary APS is underrecognized and histologically diverse, encompassing both vascular and glomerular pathology. We aimed to describe the histopathology, outcomes of biopsy-proven renal disease among primary APS and predictors of renal involvement.

Methods: Among 233 patients with primary APS (revised Sapporo criteria, 2006), Renal abnormalities defined as proteinuria >0.5 g/day and/or elevated serum creatinine with or without hematuria—were identified. Clinical, serological, histopathological and direct immunofluorescence (DIF) data were analyzed. Renal lesions were classified as per the Renal Pathology Society-2023 consensus definitions for aPL- nephropathy.

Results: Nineteen patients (8.15%) had renal abnormalities, Of these, 11 patients underwent kidney biopsy (Table 1). The median age of the biopsied cohort was 27 years (23.5-38), with 63.6% female. Hypertension was present in 63.6%. Median serum creatinine was 1.6 mg/dL (0.75-2.35), and UPCR was 4.4 g/g (1.76-7.5).Renal biopsy findings were diverse (Figure 1A), with glomerular injury more frequent than aPL nephropathy. The major glomerular finding was glomerulosclerosis and ischemic wrinkling of GBM (a sequela of TMA) seen in 27%, followed by basement membrane thickening, while interstitial inflammation was present in 64% and mesangial expansion in 73% (Table 2). Isolated Antiphospholipid nephropathy (aPL-N) was seen in 2/11 patients. Acute or chronic TMA like lesions with immune deposits or inflammatory cells seen in 4/11 patients (54.5%). Acute TMA lesions were seen in one patient, chronic lesions seen in four, while one patient had acute with chronic TMA change (Table 2). DIF was positive in most, with a full-house pattern observed in two patients, despite no lupus manifestations (Figure 1B).Treatment included warfarin (n=9, 81.8%), RAAS blockade (n=10, 90.9%), corticosteroids (n=4, 36.4%), and MMF (n=3, 27.3%). In the biopsied group (n=11), at a median 2-year follow-up, four (36.4%) achieved complete proteinuria remission (UPCR < 0.5 g/g), two (18.2%) had partial reduction, and one (9%) patient showed resolution of AKI. Of all 19 APS with renal manifestations, five had CKD and only one progressed to dialysis-dependent ESRD.On univariate analysis, arterial thrombosis (p = 0.002) and cutaneous ulcers (p = 0.0009) were significantly associated with renal involvement. On multivariable logistic regression, cutaneous ulcers independently predicted renal involvement (OR:19.5, 95% CI: 1.37-277.8, p=0.028), suggesting microvascular skin–renal overlap.

Conclusion: Renal abnormalities were identified in 8.2% of patients with primary APS. Only a minority of biopsied patients met strict histological criteria for aPL nephropathy. Most biopsies showed glomerular immune deposits or interstitial inflammation, pointing to immune-mediated renal injury in APS patients. The histologic overlap with SLE supports a pathologic continuum. Given the multitude of renal biopsy findings in Primary APS, it calls for individualized, pathology-driven treatment. Renal outcomes were favorable, with a low incidence of dialysis-requiring CKD.

Supporting image 1Renal Involvement in Primary APS: Clinical Characteristics, Biopsy Findings, and Outcomes in 11 Patients

Supporting image 2

Supporting image 3


Disclosures: R. MISHRA: None; S. PHILIP: None; R. NAUSHAD: None; A. GOPAL: None; C. Kavadichanda: None; C. MARIASELVAM: None; R. N G: None; M. Thabah: None; V. NEGI: None.

To cite this abstract in AMA style:

MISHRA R, PHILIP S, NAUSHAD R, GOPAL A, Kavadichanda C, MARIASELVAM C, N G R, Thabah M, NEGI V. Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/beyond-thrombosis-histological-spectrum-predictors-and-outcomes-of-renal-involvement-in-primary-antiphospholipid-syndrome-a-single-centre-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/beyond-thrombosis-histological-spectrum-predictors-and-outcomes-of-renal-involvement-in-primary-antiphospholipid-syndrome-a-single-centre-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology